Artikel ; Online: Potential Repurposed Therapeutics and New Vaccines against COVID-19 and Their Clinical Status.
SLAS discovery : advancing life sciences R & D
2020 Band 25, Heft 10, Seite(n) 1097–1107
Abstract: SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), was first reported in Wuhan, China, in December 2019. Since then, the virus has stretched its grip to almost all the countries in the world, affecting millions of people and causing ... ...
| Abstract | SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), was first reported in Wuhan, China, in December 2019. Since then, the virus has stretched its grip to almost all the countries in the world, affecting millions of people and causing enormous casualties. The World Health Organization (WHO) declared COVID-19 a pandemic on March 11, 2019. As of June 12, 2020, almost 7.30 million people have already been infected globally, with 413,000 reported casualties. In the United States alone, 2.06 million people have been infected and 115,000 have succumbed to this pandemic. A multipronged approach has been launched toward combating this pandemic, with the main focus on exhaustive screening, developing efficacious therapies, and vaccines for long-term immunity. Several pharmaceutical companies in collaboration with various academic institutions and governmental organizations have started investigating new therapeutics and repurposing approved drugs so as to find fast and affordable treatments against this disease. The present communication is aimed at highlighting the efforts that are currently underway to treat or prevent SARS-CoV-2 infection, with details on the science, clinical status, and timeline for selected investigational drugs and vaccines. This article is going to be of immense help to the scientific community and researchers as it brings forth all the necessary clinical information of the most-talked-about therapeutics against SARS-CoV-2. All the details pertaining to the clinical status of each therapeutic candidate have been updated as of June 12, 2020. |
|---|---|
| Mesh-Begriff(e) | Adenosine Monophosphate/analogs & derivatives ; Adenosine Monophosphate/pharmacology ; Alanine/analogs & derivatives ; Alanine/pharmacology ; Amides/pharmacology ; Animals ; Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal, Humanized/pharmacology ; Antiviral Agents/pharmacology ; COVID-19/drug therapy ; COVID-19/prevention & control ; COVID-19 Vaccines/pharmacology ; Chloroquine/pharmacology ; Clinical Trials as Topic ; Cyclopropanes ; Drug Evaluation, Preclinical ; Drug Repositioning ; Humans ; Isoindoles ; Lactams/pharmacology ; Lactams, Macrocyclic ; Mice, Transgenic ; Proline/analogs & derivatives ; Pyrazines/pharmacology ; SARS-CoV-2/drug effects ; Small Molecule Libraries/pharmacology ; Sulfonamides/pharmacology ; Vaccines, Synthetic/pharmacology |
| Chemische Substanzen | Amides ; Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Antiviral Agents ; COVID-19 Vaccines ; Cyclopropanes ; Isoindoles ; Lactams ; Lactams, Macrocyclic ; Pyrazines ; Small Molecule Libraries ; Sulfonamides ; Vaccines, Synthetic ; remdesivir (3QKI37EEHE) ; Adenosine Monophosphate (415SHH325A) ; Chloroquine (886U3H6UFF) ; danoprevir (911Z9PCQ5F) ; Proline (9DLQ4CIU6V) ; favipiravir (EW5GL2X7E0) ; sarilumab (NU90V55F8I) ; Alanine (OF5P57N2ZX) |
| Schlagwörter | covid19 |
| Sprache | Englisch |
| Erscheinungsdatum | 2020-07-21 |
| Erscheinungsland | United States |
| Dokumenttyp | Journal Article ; Research Support, Non-U.S. Gov't |
| ZDB-ID | 2885123-7 |
| ISSN | 2472-5560 ; 2472-5552 |
| ISSN (online) | 2472-5560 |
| ISSN | 2472-5552 |
| DOI | 10.1177/2472555220945281 |
| Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
| Zs.A 4911: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.